Research ArticleCommentary
Essential Aspects in Assessing the Safety Impact of Interactions between a Drug Product and Its Associated Manufacturing System
Dennis Jenke
PDA Journal of Pharmaceutical Science and Technology January 2012, 66 (1) 63-77; DOI: https://doi.org/10.5731/pdajpst.2012.00742
Dennis Jenke
References
- 1.↵
- Colton R.
- 2.↵
Equipment Construction. Code of Federal Regulations, Foods and Drugs; Title 12, Part 211.65; U.S. Government Printing Office: Washington, DC. Revised April 1, 2011. www.accessdata.fda.gov/scripts/cdhr/cfdocs/cfcfr/CFRSearch.
- 3.↵
EUDRALEX Volume 4: Good Manufacturing Practices, Medical Products for Human and Veterinary Use. European Commission: Brussels, Belgium, 1998. http://ec.europa.eu/enterprise/pharaceuticals/eudralex/homev4.htm.
- 4.↵
Available at http://www.ich.org/LOB/media/MEDIA433.pdf.
- 5.↵
- Colton R.,
- et al
- 6.↵
- Tsui V.,
- Somma M. S.,
- Zitner L. A.
- 7.↵
- Yu X.,
- Wood D.,
- Dong X.
- 8.↵
- Ding W.,
- Martin J.
- 9.↵
- Ding W.,
- Martin J.
- 10.↵
- Bestwick D.,
- Colton R.
- 11.↵
- Jenke D.
- 12.↵
Guidance for Industry. Container Closure Systems for Packaging Human Drugs and Biologics. U.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, 1999.
- 13.↵
Guideline on Plastic Immediate Packaging Materials. European Medicines Agency, CPMP/QWWP/4359/03, EMEA/CVMP/205/04, 2005.
- 14.↵
Guidance for Industry. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Chemistry, Manufacturing, and Controls Documentation. U.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, 1998.
- 15.↵
Guidance for Industry. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products: Chemistry, Manufacturing, and Controls Documentation. U.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, 2002.
- 16.↵
Best Practices for OINDP Pharmaceutical Development Programs, Leachables and Extractables. Conference Proceedings of the Product Quality Research Institute (PQRI), Washington, DC, September 20–21, 2006. See also: Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products. PQRI Leachables and Extractables Working Group, September 9, 2006. http://www.pqri.org/pdfs/LE-Recommendations-to-FDA-09-29-06.pdf.
- 17.↵
ANSI/AAMI BE83: 2006. Biological Evaluation of Medical Devices—Part 18: Chemical Characterization of Materials. Association for the Advancement of Medical Instrumentation (AAMI), American National Standards Institute (ANSI), 2006.
- 18.↵
Recommendations for Testing and Evaluation of Extractables from Single-Use Process Equipment. Bio-Process Systems Alliance: Washington, DC, 2010.
- 19.↵
- Brennan J.,
- Bing F.,
- Boone H.,
- Fernandez J.,
- Miller D.,
- Seeley B.,
- Van Deinse H.
- 20.↵
- Green S.
- 21.↵
- Wakankar A. A.,
- Wang Y. J.,
- Canova-Davis E.,
- Ma S.,
- Schmalzing D.,
- Grieco J.,
- Milby T.,
- Reynolds T.,
- Mazzarella K.,
- Hoff E.,
- Gomez S.,
- Martin-Moe S.
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 66, Issue 1
January/February 2012
Essential Aspects in Assessing the Safety Impact of Interactions between a Drug Product and Its Associated Manufacturing System
Dennis Jenke
PDA Journal of Pharmaceutical Science and Technology Jan 2012, 66 (1) 63-77; DOI: 10.5731/pdajpst.2012.00742
Jump to section
Related Articles
- No related articles found.